What is Cellectar Biosciences Inc's earnings per share (EPS)?

Cellectar Biosciences Inc (CLRB) reported diluted earnings per share of $-8.35 for fiscal year 2025. This represents a 80.1% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Cellectar Biosciences Inc Financials

CLRB

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Cellectar Biosciences Inc (CLRB) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 23 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

2/9

Cellectar Biosciences Inc passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.

Earnings Quality Low Quality

1.06x

For every $1 of reported earnings, Cellectar Biosciences Inc generates $1.06 in operating cash flow (-$23.1M OCF vs -$21.8M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

-$22.8M

YoY+55.8%

Cellectar Biosciences Inc's EBITDA was -$22.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 55.8% from the prior year.

Net Income

-$21.8M

YoY+51.1%

Cellectar Biosciences Inc reported -$21.8M in net income in fiscal year 2025. This represents an increase of 51.1% from the prior year.

EPS (Diluted)

$-8.35

YoY+80.1%

Cellectar Biosciences Inc earned $-8.35 per diluted share (EPS) in fiscal year 2025. This represents an increase of 80.1% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$23.1M

YoY+51.5%

Cellectar Biosciences Inc generated -$23.1M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 51.5% from the prior year.

Cash & Debt

$13.2M

YoY-43.3%

5Y CAGR-25.4%

10Y CAGR+12.9%

Cellectar Biosciences Inc held $13.2M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

YoY+176.1%

Cellectar Biosciences Inc had 4M shares outstanding in fiscal year 2025. This represents an increase of 176.1% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-255.3%

YoY+56.6pp

5Y CAGR-227.7pp

10Y CAGR+77.8pp

Cellectar Biosciences Inc's ROE was -255.3% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 56.6 percentage points from the prior year.

Capital Allocation

R&D Spending

$11.5M

YoY-56.0%

5Y CAGR+2.5%

10Y CAGR+8.3%

Cellectar Biosciences Inc invested $11.5M in research and development in fiscal year 2025. This represents a decrease of 56.0% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$6K

YoY-94.4%

5Y CAGR-37.6%

10Y CAGR-20.5%

Cellectar Biosciences Inc invested $6K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 94.4% from the prior year.

CLRB Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$11.5M-56.0%	$26.1M-4.1%	$27.3M+49.3%	$18.3M+3.9%	$17.6M+73.4%	$10.1M
SG&A Expenses	$11.5M-55.2%	$25.6M+119.3%	$11.7M+10.9%	$10.5M+61.2%	$6.5M+27.1%	$5.1M
Operating Income	-$23.0M+55.6%	-$51.8M-32.9%	-$39.0M-35.2%	-$28.8M-19.4%	-$24.1M-57.8%	-$15.3M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	$66K+210.0%	-$60K0.0%	-$60K	N/A	N/A
Net Income	-$21.8M+51.1%	-$44.6M-4.2%	-$42.8M-34.5%	-$31.8M-31.8%	-$24.1M-59.8%	-$15.1M
EPS (Diluted)	$-8.35+80.1%	$-41.89	$-3.50+22.4%	$-4.51-3.7%	$-4.35	$-1.84

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	$2.5M+5.6%	$2.4M-30.3%	$3.4M	N/A	$5.5M-25.2%	$7.3M+3.6%	$7.1M
SG&A Expenses	N/A	$2.3M-36.2%	$3.6M+22.7%	$3.0M	N/A	$7.8M+23.2%	$6.4M+29.4%	$4.9M
Operating Income	N/A	-$4.9M+19.7%	-$6.0M+5.7%	-$6.4M	N/A	-$13.3M+2.7%	-$13.7M-14.2%	-$12.0M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	-$4.4M+18.4%	-$5.4M+17.5%	-$6.6M	N/A	-$14.7M-1495.1%	-$919K+96.5%	-$26.6M
EPS (Diluted)	N/A	$-1.41+58.4%	$-3.39	$-0.14	N/A	$-12.13-123.4%	$-5.43-496.7%	$-0.91

CLRB Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$15.0M-41.2%	$25.5M+111.0%	$12.1M-44.1%	$21.6M-42.0%	$37.2M-36.6%	$58.7M
Current Assets	$14.0M-42.1%	$24.3M+132.0%	$10.5M-49.1%	$20.5M-43.9%	$36.6M-36.9%	$57.9M
Cash & Equivalents	$13.2M-43.3%	$23.3M+143.5%	$9.6M-51.9%	$19.9M-44.4%	$35.7M-37.5%	$57.2M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$5.1M-48.4%	$9.8M-62.1%	$25.9M+114.5%	$12.1M+190.0%	$4.2M+7.6%	$3.9M
Current Liabilities	$4.7M-49.4%	$9.4M-63.0%	$25.4M+120.5%	$11.5M+188.2%	$4.0M+12.0%	$3.6M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$8.5M-40.3%	$14.3M+194.3%	-$15.2M-285.9%	$8.2M-71.9%	$29.1M-47.0%	$54.8M
Retained Earnings	-$269.1M-8.8%	-$247.3M-22.0%	-$202.8M-26.7%	-$160.0M-6.0%	-$150.9M-19.0%	-$126.8M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$15.0M+2.4%	$14.6M+6.8%	$13.7M-14.6%	$16.0M-37.0%	$25.5M-31.7%	$37.3M+26.9%	$29.4M-31.5%	$42.9M
Current Assets	$14.0M+3.1%	$13.6M+8.0%	$12.6M-15.3%	$14.9M-38.6%	$24.3M-32.4%	$35.9M+28.6%	$27.9M-32.5%	$41.4M
Cash & Equivalents	$13.2M+5.1%	$12.6M+13.7%	$11.0M-20.6%	$13.9M-40.3%	$23.3M-32.0%	$34.3M+32.5%	$25.9M-35.4%	$40.0M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$5.1M-3.6%	$5.2M-15.7%	$6.2M-2.8%	$6.4M-34.6%	$9.8M-52.8%	$20.7M+32.8%	$15.6M-46.2%	$29.0M
Current Liabilities	$4.7M-3.3%	$4.9M-16.3%	$5.9M-2.6%	$6.0M-35.9%	$9.4M-53.8%	$20.3M+33.9%	$15.2M-46.9%	$28.6M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$8.5M+6.8%	$8.0M+31.4%	$6.1M-26.3%	$8.3M-42.3%	$14.3M-5.7%	$15.2M+22.5%	$12.4M-1.0%	$12.5M
Retained Earnings	-$269.1M-2.0%	-$263.8M-1.7%	-$259.4M-2.1%	-$253.9M-2.7%	-$247.3M-1.0%	-$245.0M-6.4%	-$230.3M-0.4%	-$229.4M

CLRB Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$23.1M+51.4%	-$47.6M-47.0%	-$32.4M-28.4%	-$25.2M-11.8%	-$22.6M-62.0%	-$13.9M
Capital Expenditures	$6K-94.4%	$104K-87.9%	$864K+282.4%	$226K+59.9%	$141K+126.7%	$62K
Free Cash Flow	-$23.1M+51.5%	-$47.7M-43.5%	-$33.2M-30.6%	-$25.4M-12.1%	-$22.7M-62.3%	-$14.0M
Investing Cash Flow	-$6K+94.4%	-$104K+87.9%	-$864K-282.4%	-$226K-59.9%	-$141K-126.7%	-$62K
Financing Cash Flow	$13.0M-78.8%	$61.4M+167.7%	$22.9M+138.7%	$9.6M+669.6%	$1.2M-97.9%	$60.5M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	-$4.3M-1.6%	-$4.3M+16.4%	-$5.1M+45.5%	-$9.4M+14.0%	-$10.9M-19.1%	-$9.2M+35.2%	-$14.1M-5.8%	-$13.4M
Capital Expenditures	N/A	N/A	N/A	N/A	$61K	$0-100.0%	$21K-1.7%	$22K
Free Cash Flow	N/A	N/A	N/A	N/A	-$11.0M-19.7%	-$9.2M+35.3%	-$14.2M-5.8%	-$13.4M
Investing Cash Flow	N/A	N/A	N/A	N/A	-$61K	$0+100.0%	-$21K+1.7%	-$22K
Financing Cash Flow	$5.0M-13.8%	$5.8M	N/A	N/A	$0-100.0%	$17.6M+1756134600.0%	$1-100.0%	$43.8M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

CLRB Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-255.3%+56.6pp	-311.9%	N/A	-389.9%-306.9pp	-83.0%-55.5pp	-27.6%
Return on Assets	-145.5%+29.5pp	-175.0%+179.2pp	-354.2%-206.9pp	-147.3%-82.4pp	-64.8%-39.1pp	-25.7%
Current Ratio	2.96+0.4	2.58+2.2	0.41-1.4	1.78-7.4	9.16-7.1	16.26
Debt-to-Equity	0.59-0.1	0.69+2.4	-1.71-3.2	1.48+1.3	0.14+0.1	0.07
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	-55.6%+34.0pp	-89.5%-9.5pp	-80.0%	N/A	-96.7%-89.3pp	-7.4%+205.7pp	-213.1%
Return on Assets	N/A	-30.4%+9.4pp	-39.8%+1.4pp	-41.2%	N/A	-39.3%-36.2pp	-3.1%+59.0pp	-62.1%
Current Ratio	2.96+0.2	2.77+0.6	2.15-0.3	2.47-0.1	2.58+0.8	1.77-0.1	1.84+0.4	1.45
Debt-to-Equity	0.59-0.1	0.66-0.4	1.02+0.2	0.78+0.1	0.69-0.7	1.37+0.1	1.26-1.1	2.32
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Edesa Biotech Inc EDSA

$51.3M

Tharimmune Inc THAR

$187.4M

Lisata Therapeutics Inc LSTA

$45.3M

Pulmatrix PULM

$4.8M

Synlogic SYBX

$6.6M

Frequently Asked Questions

Is Cellectar Biosciences Inc profitable?

No, Cellectar Biosciences Inc (CLRB) reported a net income of -$21.8M in fiscal year 2025.

What is Cellectar Biosciences Inc's EBITDA?

Cellectar Biosciences Inc (CLRB) had EBITDA of -$22.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Cellectar Biosciences Inc's return on equity (ROE)?

Cellectar Biosciences Inc (CLRB) has a return on equity of -255.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Cellectar Biosciences Inc's free cash flow?

Cellectar Biosciences Inc (CLRB) generated -$23.1M in free cash flow during fiscal year 2025. This represents a 51.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Cellectar Biosciences Inc's operating cash flow?

Cellectar Biosciences Inc (CLRB) generated -$23.1M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Cellectar Biosciences Inc's total assets?

Cellectar Biosciences Inc (CLRB) had $15.0M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Cellectar Biosciences Inc's capital expenditures?

Cellectar Biosciences Inc (CLRB) invested $6K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Cellectar Biosciences Inc spend on research and development?

Cellectar Biosciences Inc (CLRB) invested $11.5M in research and development during fiscal year 2025.

How many shares does Cellectar Biosciences Inc have outstanding?

Cellectar Biosciences Inc (CLRB) had 4M shares outstanding as of fiscal year 2025.

What is Cellectar Biosciences Inc's current ratio?

Cellectar Biosciences Inc (CLRB) had a current ratio of 2.96 as of fiscal year 2025, which is generally considered healthy.

What is Cellectar Biosciences Inc's debt-to-equity ratio?

Cellectar Biosciences Inc (CLRB) had a debt-to-equity ratio of 0.59 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Cellectar Biosciences Inc's return on assets (ROA)?

Cellectar Biosciences Inc (CLRB) had a return on assets of -145.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Cellectar Biosciences Inc's cash runway?

Based on fiscal year 2025 data, Cellectar Biosciences Inc (CLRB) had $13.2M in cash against an annual operating cash burn of $23.1M. This gives an estimated cash runway of approximately 7 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Cellectar Biosciences Inc's Piotroski F-Score?

Cellectar Biosciences Inc (CLRB) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Cellectar Biosciences Inc's earnings high quality?

Cellectar Biosciences Inc (CLRB) has an earnings quality ratio of 1.06x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.